The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.
 
Ahmed Omar Kaseb
Stock and Other Ownership Interests - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences
Honoraria - Bayer Health; Bayer Health; Bayer Health; Bayer Health; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Exelixis; Merck; Merck; Merck; Merck
Consulting or Advisory Role - Bayer Health; Bayer Health; Bayer Health; Bayer Health; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Exelixis; Merck; Merck; Merck; Merck
Research Funding - Bayer/Onyx; Bayer/Onyx; Bayer/Onyx; Bayer/Onyx; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Genentech; Genentech; Genentech; Genentech; Merck; Merck; Merck; Merck
Travel, Accommodations, Expenses - Bayer/Onyx; Bayer/Onyx; Bayer/Onyx; Bayer/Onyx; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Exelixis; Merck; Merck; Merck; Merck
 
Dan G. Duda
No Relationships to Disclose
 
Hop Sanderson Tran Cao
No Relationships to Disclose
 
Yehia I. Abugabal
No Relationships to Disclose
 
Luis M. Vence
No Relationships to Disclose
 
Asif Rashid
No Relationships to Disclose
 
Roberto Pestana
No Relationships to Disclose
 
Jorge M. Blando
No Relationships to Disclose
 
Shalini Singh
No Relationships to Disclose
 
Jean-Nicolas Vauthey
No Relationships to Disclose
 
Manal Hassan
No Relationships to Disclose
 
Hesham M. Amin
No Relationships to Disclose
 
Aliya Qayyum
No Relationships to Disclose
 
Yun Shin Chun
No Relationships to Disclose
 
Ching-Wei David Tzeng
No Relationships to Disclose
 
Divya Sakamuri
No Relationships to Disclose
 
Robert A. Wolff
Patents, Royalties, Other Intellectual Property - Royalties from McGraw-Hill: Editor: M.D. Anderson Manual of Medical Oncology, 3rd edition.; Royalties from McGraw-Hill: Editor: M.D. Anderson Manual of Medical Oncology, 3rd edition.; Royalties from McGraw-Hill: Editor: M.D. Anderson Manual of Medical Oncology, 3rd edition.; Royalties from McGraw-Hill: Editor: M.D. Anderson Manual of Medical Oncology, 3rd edition.
 
James C. Yao
No Relationships to Disclose
 
James Patrick Allison
Stock and Other Ownership Interests - Amgen; Amgen; Amgen; Amgen; Amgen (I); Amgen (I); Amgen (I); Amgen (I); Apricity Health (I); Apricity Health (I); Apricity Health (I); Apricity Health (I); Apricity Therapeutics; Apricity Therapeutics; Apricity Therapeutics; Apricity Therapeutics; AstraZeneca (I); AstraZeneca (I); AstraZeneca (I); AstraZeneca (I); BioAtla; BioAtla; BioAtla; BioAtla; BioAtla (I); BioAtla (I); BioAtla (I); BioAtla (I); BioMX (I); BioMX (I); BioMX (I); BioMX (I); Codiak Biosciences; Codiak Biosciences; Codiak Biosciences; Codiak Biosciences; Codiak Biosciences (I); Codiak Biosciences (I); Codiak Biosciences (I); Codiak Biosciences (I); Constellation Pharmaceuticals; Constellation Pharmaceuticals; Constellation Pharmaceuticals; Constellation Pharmaceuticals; Constellation Pharmaceuticals (I); Constellation Pharmaceuticals (I); Constellation Pharmaceuticals (I); Constellation Pharmaceuticals (I); Forty Seven; Forty Seven; Forty Seven; Forty Seven; Forty Seven (I); Forty Seven (I); Forty Seven (I); Forty Seven (I); GlaxoSmithKline (I); GlaxoSmithKline (I); GlaxoSmithKline (I); GlaxoSmithKline (I); Hummingbird; Hummingbird; Hummingbird; Hummingbird; Hummingbird (I); Hummingbird (I); Hummingbird (I); Hummingbird (I); ImaginAb; ImaginAb; ImaginAb; ImaginAb; ImaginAb (I); ImaginAb (I); ImaginAb (I); ImaginAb (I); Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics (I); Jounce Therapeutics (I); Jounce Therapeutics (I); Jounce Therapeutics (I); Marker Therapeutics; Marker Therapeutics; Marker Therapeutics; Marker Therapeutics; Merck; Merck; Merck; Merck; Merck (I); Merck (I); Merck (I); Merck (I); Neon Therapeutics; Neon Therapeutics; Neon Therapeutics; Neon Therapeutics; Neon Therapeutics (I); Neon Therapeutics (I); Neon Therapeutics (I); Neon Therapeutics (I); Oncolytics (I); Oncolytics (I); Oncolytics (I); Oncolytics (I); Pieris Pharmaceuticals (I); Pieris Pharmaceuticals (I); Pieris Pharmaceuticals (I); Pieris Pharmaceuticals (I); Polaris; Polaris; Polaris; Polaris; Polaris (I); Polaris (I); Polaris (I); Polaris (I); Tvardi therapeutics; Tvardi therapeutics; Tvardi therapeutics; Tvardi therapeutics
Patents, Royalties, Other Intellectual Property - Inventor of a patent licensed to Merck; Inventor of a patent licensed to Merck; Inventor of a patent licensed to Merck; Inventor of a patent licensed to Merck; Inventor of a patent owned by Memorial Sloan-Kettering Cancer Center and licensed by Jounce Therapeutics; Inventor of a patent owned by Memorial Sloan-Kettering Cancer Center and licensed by Jounce Therapeutics; Inventor of a patent owned by Memorial Sloan-Kettering Cancer Center and licensed by Jounce Therapeutics; Inventor of a patent owned by Memorial Sloan-Kettering Cancer Center and licensed by Jounce Therapeutics
 
Padmanee Sharma
Stock and Other Ownership Interests - Apricity Health; Apricity Health; Apricity Health; Apricity Health; Apricity Health (I); Apricity Health (I); Apricity Health (I); Apricity Health (I); BioAtla; BioAtla; BioAtla; BioAtla; BioAtla (I); BioAtla (I); BioAtla (I); BioAtla (I); Codiak Biosciences; Codiak Biosciences; Codiak Biosciences; Codiak Biosciences; Codiak Biosciences (I); Codiak Biosciences (I); Codiak Biosciences (I); Codiak Biosciences (I); Constellation Pharmaceuticals; Constellation Pharmaceuticals; Constellation Pharmaceuticals; Constellation Pharmaceuticals; Constellation Pharmaceuticals (I); Constellation Pharmaceuticals (I); Constellation Pharmaceuticals (I); Constellation Pharmaceuticals (I); Dragonfly Therapeutics; Dragonfly Therapeutics; Dragonfly Therapeutics; Dragonfly Therapeutics; Forty Seven; Forty Seven; Forty Seven; Forty Seven; Forty Seven (I); Forty Seven (I); Forty Seven (I); Forty Seven (I); Hummingbird; Hummingbird; Hummingbird; Hummingbird; ImaginAb; ImaginAb; ImaginAb; ImaginAb; ImaginAb (I); ImaginAb (I); ImaginAb (I); ImaginAb (I); Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics (I); Jounce Therapeutics (I); Jounce Therapeutics (I); Jounce Therapeutics (I); Lytix Biopharma; Lytix Biopharma; Lytix Biopharma; Lytix Biopharma; Lytix Biopharma (I); Lytix Biopharma (I); Lytix Biopharma (I); Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics; Marker Therapeutics; Marker Therapeutics; Marker Therapeutics (I); Marker Therapeutics (I); Marker Therapeutics (I); Marker Therapeutics (I); Neon Therapeutics; Neon Therapeutics; Neon Therapeutics; Neon Therapeutics; Neon Therapeutics (I); Neon Therapeutics (I); Neon Therapeutics (I); Neon Therapeutics (I); Oncolytics; Oncolytics; Oncolytics; Oncolytics; Polaris; Polaris; Polaris; Polaris; Polaris (I); Polaris (I); Polaris (I); Polaris (I); Tvardi Therapeutics (I); Tvardi Therapeutics (I); Tvardi Therapeutics (I); Tvardi Therapeutics (I)
Consulting or Advisory Role - Apricity Health; Apricity Health; Apricity Health; Apricity Health; Apricity Health (I); Apricity Health (I); Apricity Health (I); Apricity Health (I); BioAtla; BioAtla; BioAtla; BioAtla; BioAtla (I); BioAtla (I); BioAtla (I); BioAtla (I); Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Codiak Biosciences; Codiak Biosciences; Codiak Biosciences; Codiak Biosciences; Codiak Biosciences (I); Codiak Biosciences (I); Codiak Biosciences (I); Codiak Biosciences (I); Constellation Pharmaceuticals; Constellation Pharmaceuticals; Constellation Pharmaceuticals; Constellation Pharmaceuticals; Constellation Pharmaceuticals (I); Constellation Pharmaceuticals (I); Constellation Pharmaceuticals (I); Constellation Pharmaceuticals (I); Dragonfly Therapeutics; Dragonfly Therapeutics; Dragonfly Therapeutics; Dragonfly Therapeutics; Dragonfly Therapeutics (I); Dragonfly Therapeutics (I); Dragonfly Therapeutics (I); Dragonfly Therapeutics (I); Forty Seven; Forty Seven; Forty Seven; Forty Seven; Forty Seven (I); Forty Seven (I); Forty Seven (I); Forty Seven (I); Hummingbird; Hummingbird; Hummingbird; Hummingbird; Hummingbird (I); Hummingbird (I); Hummingbird (I); Hummingbird (I); ImaginAb; ImaginAb; ImaginAb; ImaginAb; ImaginAb (I); ImaginAb (I); ImaginAb (I); ImaginAb (I); Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics (I); Jounce Therapeutics (I); Jounce Therapeutics (I); Jounce Therapeutics (I); Lytix Biopharma; Lytix Biopharma; Lytix Biopharma; Lytix Biopharma; Lytix Biopharma (I); Lytix Biopharma (I); Lytix Biopharma (I); Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics; Marker Therapeutics; Marker Therapeutics; Marker Therapeutics (I); Marker Therapeutics (I); Marker Therapeutics (I); Marker Therapeutics (I); Neon Therapeutics; Neon Therapeutics; Neon Therapeutics; Neon Therapeutics; Neon Therapeutics (I); Neon Therapeutics (I); Neon Therapeutics (I); Neon Therapeutics (I); Oncolytics; Oncolytics; Oncolytics; Oncolytics; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Polaris; Polaris; Polaris; Polaris; Polaris (I); Polaris (I); Polaris (I); Polaris (I); Tvardi Therapeutics (I); Tvardi Therapeutics (I); Tvardi Therapeutics (I); Tvardi Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patent licensed to Jounce; Own patent licensed to Jounce; Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I); Own patents licensed to BMS, Jounce & Merck (I); Own patents licensed to BMS, Jounce & Merck (I); Own patents licensed to BMS, Jounce & Merck (I)